Announcements Trials
Browse Landscape

Phase

Phase 1 14Phase 2 3Phase 3 2Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 20Sarcoma 3Other solid neoplasm 3Tumor-Agnostic 2Thoracic 2Head & Neck 2Genitourinary 2NET 1Gynecologic 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Neoplasm Metastasis 1Adenocarcinoma 1

Interventions

pembrolizumab 18Nivolumab 18Gemcitabine 9Ipilimumab 8Cisplatin 8Carboplatin 8Capecitabine 8Paclitaxel 6Cetuximab 6atezolizumab 5Irinotecan 5Docetaxel 5Cyclophosphamide 5Bevacizumab 5avelumab 4Trastuzumab 4Fluorouracil 4trametinib 3spartalizumab 3Specimen Handling 3Pemetrexed 3Leucovorin 3Everolimus 3Dexamethasone 3Biopsy 3urelumab 2toripalimab 2tislelizumab 2ribociclib 2repotrectinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × regorafenib × Tumor-Agnostic × Clear all
NCT03722108 2023-10-16

REGIRI

UNICANCER

Phase 1/2 Terminated
89 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT01896856 2020-10-06

Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
118 enrolled 16 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡